Medical Ventures Corp.

Industry:

Medical Devices & Equipment

Description

Medical Ventures Corp. ("MEV") develops, manufactures and distributes medical devices and is focused on the development and commerciaiization of medical devices which clearly address a clinical need in the cardiovascular marketplace. Our strategy is to acquire and develop technologies and products that are within two years of commercialization and to increase the value of our technologies through the commercialization process.

MEV's business operations started in March 2002 with the acquisition of PM Devices Inc. ("PMD"), which offered a promising technology and products using a unique tissue processing technology on bovine pericardial tissue to produce a number of patch products used in cardiac reconstruction and repair. MEV is also looking to expand its portfolio of tissue products through the development of new value-added products which uses its tissue processing technology.

In May 2003, MEV entered the rapidly growing interventional cardiology market with the acquisition of Angiometrx Inc., a catheter based technology development company. Angiometrx had a promising new technology called the MetricathÔ System with near term commercialization potential enabling MEV to further leverage its manufacturing and distribution capability.

As a result of MEV's growth, MEV has formed into two divisions: tissue products within PMD and catheter products within Angiometrx. The focus in both divisions is the commercialization of the cardiovascular medical devices currently in the MEV's product portfolio, and the development of new products based upon these two core technologies.

Its vision is to develop a portfolio of technologies and products from which MEV gains revenue from distribution, licensing or sale of each of the individual products. MEV is focused on two specific market areas: large under exploited market opportunities where few technical solutions currently exist and niche market opportunities where the revenue potential for the products may be $50-$250 million.

News Archive

Canada Cardiovascular Devices Market Analysis and Forecasts to 2015. M2 Presswire; 9/10/2009 ...Corporation, ev3 Inc., C.R. Bard, Inc., Medical Ventures Corp., Baylis Medical Company Inc., Interface...Corporation - ev3 Inc. - C.R. Bard, Inc. - Medical Ventures Corp. - Baylis Medical Company I ...more

Dave Franchino and Ken Martin Present "Leveraging Innovation Partnerships". Heart Disease Weekly; 7/26/2009 ...pioneering new therapies to minimize the invasiveness of treating aortic valve disease. Investors include Accuitive Medical Ventures, Boston Scientific (NYSE:BSX), Finistere, Firstmark Capital, Oakwood, ONSET Ventures and SV Life Sciences... ...more

40+ Privately-Held Emerging Medical Technology Companies to Present Online February 3, 2010, Hosted by Life Science Intelligence. Medical Devices & Surgical Technology Week; 12/20/2009 ...Technologies Spotlight - an online meeting being held on February 3, 2010 at 11 a.m. Eastern, sponsored by Orange Coast Medical Ventures and Rutan. The program will feature select privately-held companies, at various stages of development, aiming... ...more